KEY TAKEAWAY: The pharma industry’s top trade group on Tuesday launched a new series of ads as part of its drug pricing campaign aimed at blaming cost increases on insurers and pharmacy benefit managers. However, it’s trying to bail water from a sinking ship. Continue reading
As more and more pharma and biotech companies invest more money in digital marketing one has to wonder if they can attract digital talent in a regulated industry. Continue reading
From JAMA: “Although prices are often justified by the high cost of drug development, there is no evidence of an association between research and development costs and prices ; rather, prescription drugs are priced in the United States primarily on the basis of what the market will bear”. And I guess most pharma executives believe the market can bear a lot more. Continue reading
KEY IDEA: The objective of DTC marketing is, and will always be, to generate new Rx’s for the product. While the idea of bringing patients together in community and sharing information is a good one too many drug companies are not willing to take the risk(s). Continue reading
- Worldwide sales, which neared $300 billion in 2015, were up only 5% over that timeframe, indicating drug companies were squeezing more pro t from every sale.
KEY TAKEAWAY: GSK and Novartis have gone to the outside to hire senior digital marketing people with CPG experience. While these moves are long overdue is it enough or is pharma waiting at the airport for their ship to come in? Continue reading